Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0729233 (Thoracic)
 6,478 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 74-year-old man with primary lung cancer developed preoperative empyema but was successfully managed surgically. The patient was given a diagnosis of c-T2N1M0, stage IIB, moderately differentiated squamous cell carcinoma, but before surgery pneumothorax and empyema developed, resulting from rupture of the carcinoma. Thoracic drainage, lavage and systemic administration of antibiotics improved his empyema. As there were no malignant cells in the drainage fluid, right middle-lower bilobectomy, empyemal cavity resection and lymph node dissection were performed. The bronchial stump was covered with an intercostal muscle flap. Thoracic drainage, lavage and systemic administration of antibiotics were performed for 6 days following the operation. The patient was discharged on the 27th postoperative day without any complications having developed. The pathological diagnosis of the tumor was p-T4N2(#7)M0, stage IIIB, br(-), ly(+), v(+), p3(pleura), pm1 and d0. He died of recurrence at home 18 months after the operation. We believe the following to be the minimum requirements for surgical management of such patients: (1) immediate thoracic cavity drainage and lavage with systemic antibiotic therapy, aiming at infection control before surgery; (2) prophylactic lavage of the thoracic cavity during and after surgery and (3) coverage of the bronchial stump with an adequate flap. Six reported cases of primary lung cancer with preoperative empyema are also discussed.
 ...
PMID:Surgical management of primary lung cancer in an elderly patient with preoperative empyema. 1067 61

The results of MRI in 81 patients with morphologically verified lung cancer, mainly Stages IIIA and IIIB, were analyzed. They were compared with CT data in 37 cases and surgical findings in 28. MRI was performed by using Magnaview 0.04 T and Vectra 0.5 T apparatus in the T1- and T2-weighted SE and PC sequences as well in the fat-suppression mode. Thoracic metastases were evaluated from the direct signs tumor spread into the adjacent tissue and vessels. The criteria for the involvement of lymph nodes were their over 1-cm enlargement and characteristic changes in the intensity of signals from them. CT was found to yield less information on pleural, pericardial, and vascular invasion (66-75% sensitivity). MRI detected this type of cancer spread (88-94% sensitivity). Both techniques have nearly equal sensitivities in revealing intrathoracic lymphadenopathy. The interpretation of MRI data did not depend on the voltage of a magnetic field. It is recommended that MRI should be made after CT when there is a need for assessing large vessels or for making clear the data that remain open to question following CT.
 ...
PMID:[Magnetic resonance tomography in the diagnosis of lung metastases in the mediastinum and thorax]. 1071 24

The new international lymph node classification adopted by the American Joint Committee on Cancer (AJCC) and the Union Internationale Contre le Cancer (UICC) is described and illustrated with computed tomography (CT). Anatomic landmarks for 14 hilar, intrapulmonary, and mediastinal lymph node stations are designated. Main differences between the new international classification and the American Thoracic Society (ATS) one are emphasized. In particular, mediastinal pleural reflection is now used to differentiate N2 from N1 nodes. The ATS 10L (left peribronchial nodes) and 10R (right tracheobronchial nodes) stations are now replaced by the AJCC-UICC station 10 (hilar nodes) and the AJCC-UICC station 4 (lower paratracheal, including azygos, nodes), respectively. This very important difference from the ATS classification helps classify the 4 lower paratracheal nodes as N2 nodes, even though the pleural reflection is not seen with CT. The 5 AJCC-UICC nodes are renamed subaortic nodes instead of aortopulmonary ATS nodes. Paraortic nodes, which previously were classified as 5 ATS nodes, are now included with the 6 AJCC-UICC nodes (now renamed paraaortic nodes instead of anterior mediastinal ATS nodes). This change helps accurate labeling because the border between 5 and 6 ATS nodes was not always clear on CT scans. Radiologists should be familiar with this new classification to be able to more accurately compare the lung cancer staging done in different institutions around the world.
 ...
PMID:CT demonstration of the 1996 AJCC-UICC regional lymph node classification for lung cancer staging. 1075 15

Limited information is available in the medical literature on thoracic reirradiation for patients with recurrent/persistent lung carcinoma or new primary lung tumors. Controversy exists regarding the retreatment because of concerns regarding the risk of radiation toxicity. The medical and radiotherapeutic records of more than 1,500 patients with lung cancer seen in the Department of Radiation Oncology at Thomas Jefferson University Hospital from 1982 through 1997 were searched. Twenty-three patients with history of previous thoracic radiation therapy underwent thoracic reirradiation for either biopsy-proven and/or radiographically evident tumor recurrence, metastasis, or second lung primary. Most patients were reirradiated because of progressive dyspnea, cough, thoracic pain, or hemoptysis. Each of these symptoms was evaluated separately with regard to the subjective response to reirradiation. The median follow-up time from completion of reirradiation to last correspondence with the patient and/or family was 3.2 months, with a range of 0 to 17.5 months. In six patients with hemoptysis, a decrease or resolution of this symptom was noted. Of five patients with thoracic pain attributed to carcinoma, four noted an improvement in pain after reirradiation. Of 15 patients with cough, 9 had an improvement in cough, and of 15 patients with dyspnea, 11 had an improvement. Thoracic reirradiation is an effective modality in patients with hemoptysis, thoracic pain, cough, and dyspnea attributed to a radiographically defined recurrence and/or progression of lung cancer.
 ...
PMID:Thoracic reirradiation for symptomatic relief after prior radiotherapeutic management for lung cancer. 1077 77

A study to evaluate the efficacy of cisplatin, doxorubicin, and etoposide chemotherapy with combined radiotherapy was undertaken in 26 patients with limited disease-small-cell lung cancer. Patients were treated with cisplatin (80 mg/m2) intravenously (i.v.) on day 1, doxorubicin (30 mg/m2) i.v. on day 1, and etoposide (80 mg/m2) i.v. on days 1, 3, and 5, every 4 weeks for four cycles. Thoracic irradiation of 40 Gy in 20 fractions was delivered during 4 weeks to the primary site starting on day 8 of the second cycle of chemotherapy. The objective response rate was 100%. A complete response was observed in 10 patients (38%). The median survival time was 23 months, and the 3-year survival rate was 42%. Seven patients (27%) continued to survive at least 8 years and remain free from disease. Grade III/IV leukopenia was observed in 25 patients (96%). Grade III/IV thrombocytopenia developed in 19 patients (73%). Grade III/IV esophagitis was not seen. Interstitial pneumonitis occurred in two patients. This regimen is effective and has acceptable toxicity for use in the treatment of limited disease-small-cell lung cancer.
 ...
PMID:A phase II study of combined chemoradiotherapy for limited disease-small-cell lung cancer. 1077 84

The Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S) has been enrolled in a prospective data collection project from patients with bronchogenic carcinoma who underwent thoracotomy in 20 Spanish hospitals from October 1993 to September 1997. In this 4-year period, 2995 patients were registered and demographic, clinical, biological, diagnostic, surgical, pathological and follow-up information collected in a homogeneous way. The main objectives of the Group are to describe the population with lung cancer at the time of diagnosis in Spain; to analyse operative morbi-mortality; and to identify multiple prognostic factors. So far, some preliminary results have already been published concerning the description of the population, the methodology of the Group, the assessment of morbi-mortality, and the validation of the 1997 TNM classification.
 ...
PMID:The Spanish data base for the staging of lung cancer. Experience of the Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S). 1080 71

The aims of the study were to assess the degree of ploidy and determine whether it had any influence on the remission time and survival of surgically treated patients with squamous cell lung cancer. The results were then related to the clinical staging, grading, size and location of the tumor. Tissue samples of squamous cell lung carcinoma (n=80) resected between 1995 and 1996 in the Department of Thoracic Surgery at University of Medical Sciences in Poznan were prepared using the modified Hedley's method. The measurements were made by means of a Cytoron Absolute flow cytometer. Abnormal (aneuploid) DNA was found in 45% of the tumors. In the 2-year observation period significantly more patients with aneuploid tumors died (75%) than those with diploid tumors (43.2%), P<0.05. No significant correlation was found between the ploidy and frequency of metastasis to regional lymph nodes, tumor size, location or grading. Estimation of the DNA content in cancer cells appears to be a significant prognostic factor. Furthermore measurement of the DNA content can be useful after surgery to estimate the risk of recurrence.
Lung Cancer 2000 Sep
PMID:The prognostic value of DNA content analysis in patients with squamous cell lung cancer treated surgically. 1099 18

The West Japan Lung Cancer Study Group (recently renamed the West Japan Thoracic Oncology Group) is a non-government, non-profit regional scientific organization whose objectives are to conduct clinical research and treatment of lung cancer, and to promote lung cancer expertise among thoracic physicians and radiologists in west Japan. Since 1990, a total of 46 institutes have joined and established the rules of a society. Our major interests are phase II and III trials of chemotherapy in lung cancer. We also have participated in activities with the Japan Clinical Oncology Group (JCOG), which is supported by the National Cancer Center in Tokyo. Additionally, we have conducted phase II and III trials with the support of Japanese pharmaceutical companies. This support allows us to conduct reliable, large-scale randomized trials. Our organization's main problems are unrefined data management and few qualified statisticians, due in part to a lack of funding.
 ...
PMID:Originality benefit and difficulty of clinical research in the West Japan Lung Cancer Group. 1099 19

Although there have been several attempts in dividing N2 patients into several subgroups on the basis of different prognoses, the correct treatment for these patients is still a moot point. Even multimodal treatment, which is the most common therapy used, does not result in a consistent outcome. The aim of our study is to assess the prognostic value of the extent of mediastinal lymph node infiltration in surgically treated non-small cell lung cancer (NSCLC). From January 1990 to December 1997, 682 patients underwent surgery for NSCLC at the Thoracic Surgery Unit, University Hospital of Siena, 87 of which (12%) had mediastinal involvement. Studies on the number of lymph node stations show that those with one station involved tend to have a better 5-year survival rate with respect to the others. We studied the number of lymph node stations by using a new critique based on the percentage of lymph node infiltration. The percentage is obtained from a ratio of the number of involved nodes to the total number of nodes removed. The result was an improved 5-year survival ratio in patients with lymph node infiltration, lower than 50% with respect to the others, and the difference was significant (P=0.0001). It appears that surgery may be the most suitable option for treating those N2 patients that we consider to be in 'early N2 phase', in view of long term survival. Although an invasive technique like mediastinoscopy seems to be the appropriate indicator in selecting N2 patients, it does not allow the calculation of the ratio a priori.
Lung Cancer 2000 Nov
PMID:Assessing the prognostic value of the extent of mediastinal lymph node infiltration in surgically-treated non-small cell lung cancer (NSCLC). 1108 3

This consensus statement by the Society of Thoracic Radiology is a summary of the current understanding of low dose computed tomography (CT) for screening for lung cancer. Lung cancer is the most common fatal malignancy in the industrialized world. Unlike the next three most common cancers, screening for lung cancer is not currently recommended by cancer organizations. Improvements in CT technology make lung screening feasible. Early prevalence data indicate that about two-thirds of lung cancers that are detected by CT screening are at an early stage. Other data support the postulate that patients with lung cancers detected at this early stage have better rates of survival. Whether this will translate into an improved disease specific mortality is yet to be demonstrated. The suggested technical protocols, selection criteria, and method of handling the numerous benign nodules that are detected are discussed. It is the consensus of this committee that mass screening for lung cancer with CT is not currently advocated. Suitable subjects who wish to participate should be encouraged to do so in controlled trials, so that the value of CT screening can be ascertained as soon as possible.
 ...
PMID:A consensus statement of the Society of Thoracic Radiology: screening for lung cancer with helical computed tomography. 1114 94


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>